Danny Bartel, MD
Neurology · Wichita Falls, TXNPI 1679535843
Payments from drug & device makers
Across 1,913 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- EMD Serono, Inc.$7K
- Biogen$3K
- Supernus Pharmaceuticals, Inc.$3K
- Acadia Pharmaceuticals Inc$2K
- Novartis$2K
- plus $20K from 54 others
What the payments were for
- Consulting fees$5,28011%
- Speaking & faculty fees$7,70417%
- Travel & lodging$1,5153%
- Food & beverage$31,26567%
- Education$7082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$7,768
- Mavenclad$6,147
- QELBREE$801
- Infinity DBS Pulse Generators$464
- DAXXIFY$256
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$256
- VNS Therapy$217
- ZEPOSIA$180
- SOLIRIS$124
- PURIFIED CORTROPHIN GEL$113
- RNS Neurostimulator Kit$102
How this compares
$46,471 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 68 | $859,557 |
| TysabriNatalizumab | 74 | $625,686 |
| Kesimpta PenOfatumumab | 63 | $551,828 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 42 | $528,271 |
| ZeposiaOzanimod Hydrochloride | 36 | $487,486 |
| NuplazidPimavanserin Tartrate | 63 | $448,125 |
| NourianzIstradefylline | 141 | $408,674 |
| RituxanRituximab | 15 | $193,639 |
| RadicavaEdaravone | 13 | $160,557 |
| AptiomEslicarbazepine Acetate | 131 | $158,470 |
| VumerityDiroximel Fumarate | 17 | $144,905 |
| Nurtec OdtRimegepant Sulfate | 93 | $128,585 |
| AubagioTeriflunomide | 14 | $127,902 |
| MayzentSiponimod | 11 | $122,642 |
| IngrezzaValbenazine Tosylate | 11 | $85,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $360 | $859,55768 claims |
| BiogenTysabri, Vumerity | $2,729 | $770,59291 claims |
| Grifols USA, LLCGamunex-C | $256 | $528,27142 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $114 | $487,48636 claims |
| Acadia Pharmaceuticals IncNuplazid | $2,046 | $448,12563 claims |
| Kyowa Kirin, Inc.Nourianz | $544 | $408,674141 claims |
| PfizerNurtec Odt, Eliquis, Premarin | $721 | $175,340189 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $795 | $158,470131 claims |
| SanofiAubagio | $999 | $127,90214 claims |
| NovartisMayzent | $1,685 | $122,64211 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,406 | $85,35711 claims |
| AbbVieLinzess, Qulipta, Ubrelvy | $9,323 | $57,81467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.
Other neurology in Wichita Falls
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.